#ACRbest Abstracts – Day 4 Save

Jack Cush, MD

Nov 16, 2023 5:49 pm

While there wasn’t much original new programming and research presented on the final day, that didn’t slow the RheumNow faculty from tweeting the noteworthy “Best of ACR” abstracts. Enjoy these below.

TEST FOR SERONEGATIVE RA?

Last abstract of #ACR23 was #ACRBest

Plasma cfDNA signatures (synovial mapped) to identify RA vs OA, other inflamm arthritis

Great performance, even with seroneg RA

A blood test to:
diagnose
?phenotype
?identify best b/tsDMARD
Could be massive

Peter Taylor ABST2586 @RheumNow pic.twitter.com/tJX2jXV0Oe
— David Liew (@drdavidliew) November 15, 2023

NEW FOR RA

#ACR23 Abstr#2576 Promising therapy in Dermatomyositis. Phase 2 RCT showed rapid improvement in skin, muscle & patient reported outcomes as fast as Week 4 in PF-06823859 (anti-IFN-B) vs PBO. Could be useful to treat in either skin or muscle predominant patients @RheumNow #ACRBest pic.twitter.com/Rj1k1z0Tsz
— Md Yuzaiful Md Yusof (@Yuz6Yusof) November 15, 2023

Telitacicept a recombinant fusion protein targeting, neutralizing BLyS and APRIL, phase 3 study in RA MTX-IR at 24 wk, ACR20 (60% vs 27% PBO), ACR50 (21% vs 6% PBO), reduced DAS28-ESR, no radiographic progression, Wang L Abst#L20 #ACR23 #ACRBest @RheumNow https://t.co/nuvizqQZsR pic.twitter.com/PRtlea3AqU
— Dr. Antoni Chan (@synovialjoints) November 15, 2023

#ACR23 Abstr#2576 Promising therapy in Dermatomyositis. Phase 2 RCT showed rapid improvement in skin, muscle & patient reported outcomes as fast as Week 4 in PF-06823859 (anti-IFN-B) vs PBO. Could be useful to treat in either skin or muscle predominant patients @RheumNow #ACRBest pic.twitter.com/Rj1k1z0Tsz
— Md Yuzaiful Md Yusof (@Yuz6Yusof) November 15, 2023

After 3 years, 25% (95% CI: 13 to 38) remained flare-free in the tapering TNFi group compared to 85% (70 to 93) in the stable TNFi group, hazard ratio for flare of 9.4 (3.9 to 22.8), ARCTIC REWIND, Kjorholt K, LB Abst#L07 #ACR23 #ACRBest @RheumNow https://t.co/fqxfU3jE0q pic.twitter.com/J0qBeKNsEW
— Dr. Antoni Chan (@synovialjoints) November 15, 2023

ARTIC REWIND RCT 3 yrs csDMARD withdrawal

38% 3yrs csDMARDs free remission vs. 80% stable dose gpe

75% recovery after restart

Rx progression 19% in half dose gpe

More use bioDMARDs (18%) & GCs (50%) withdraw gpe

Trends towards lower infections@RheumNow #ACR23 #ACRBest pic.twitter.com/jhOINV7LLS
— Aurelie Najm (@AurelieRheumo) November 15, 2023

Antifibrotics in RA-ILD @Juge_P_A Discontinuation in 46% (Mainly GI). Improved FVC trajectory - almost stops decline. Abstr#2479 #ACR23 #ACRbest @RheumNow https://t.co/nZW6TVKefL pic.twitter.com/5BX3PhFhOK
— Richard Conway (@RichardPAConway) November 14, 2023

LUPUS

Agimeteran a TLR7/8i 30 mg in #cutaneous #lupus which differentiated from placebo. Small single site #RCT. Far more pts improved #CLASI by 50% vs PBO #ACR23 #ACRbest ⁦@RheumNow⁩ ⁦@ACRheum⁩ L15 In larger RCT now! pic.twitter.com/zssjgpydVY
— Janet Pope (@Janetbirdope) November 15, 2023

A#2427 #ACR23 @RheumNow
PR3+ cell abundance higher in prolif LN, more than membranous. Mostly in tuberulointerstitium
Density of PR3+ higher in glomueruli of prolif LN
Correlates with activity, not chronicity
Urinary PR3 predict renal fxn loss at 3y@jhrheumatology @andreafava pic.twitter.com/vvC8lgZgWO
— Eric Dein (@ericdeinmd) November 14, 2023

SYSTEMIC SCLEROSIS

1st Large real world observational head to head study on tx of Systemic sclerosis - ILD

No difference in treatment effectiveness of FVC change between tocilizumab, rituximab, mycophenolate and cyclophosphamide!@RheumNow #ACR23 Abs#2596#ACRBest pic.twitter.com/GaSnZSCcnZ
— Robert B Chao, MD (@doctorRBC) November 15, 2023

DERMATOMYOSITIS

#ACR23 Abstr#2576 Promising therapy in Dermatomyositis. Phase 2 RCT showed rapid improvement in skin, muscle & patient reported outcomes as fast as Week 4 in PF-06823859 (anti-IFN-B) vs PBO. Could be useful to treat in either skin or muscle predominant patients @RheumNow #ACRBest pic.twitter.com/Rj1k1z0Tsz
— Md Yuzaiful Md Yusof (@Yuz6Yusof) November 15, 2023

IGG4

Peng et al. 146 IgG4-RD in remission on immunomodulators+GC. 18 month follow-up. Withdraw IM+GC - 52% flare. Withdraw GC + continue IM 14.2% flare. Continue both 12.2% flare. Clear message that ongoing IM is the way Abstr#L16 #ACR23 #ACRbest @RheumNow https://t.co/3CAQhyTYqq pic.twitter.com/qr1GOSvJYg
— Richard Conway (@RichardPAConway) November 15, 2023

PREGNANCY

#ACRBest https://t.co/nx3bzhmeBW
— Aurelie Najm (@AurelieRheumo) November 15, 2023

POTPOURRI

#ACR23 Abstr#2576 Promising therapy in Dermatomyositis. Phase 2 RCT showed rapid improvement in skin, muscle & patient reported outcomes as fast as Week 4 in PF-06823859 (anti-IFN-B) vs PBO. Could be useful to treat in either skin or muscle predominant patients @RheumNow #ACRBest pic.twitter.com/Rj1k1z0Tsz
— Md Yuzaiful Md Yusof (@Yuz6Yusof) November 15, 2023

#ACR23 Late-Breaking Abstr#L19 IA steroid can help osteoarthritis knee pain but effect & duration are variable. Phase 3 RCT: improvement in ADP & WOMAC pain favouring TLC5999 (liposomal modification of DEX) vs PBO at all timepoints inc. after repeated injection @RheumNow #ACRBest pic.twitter.com/xUhoFHPExr
— Md Yuzaiful Md Yusof (@Yuz6Yusof) November 15, 2023

How do we treat #VEXAS - UBA1 mutation
Large multicenter cohort - 110 pts, 99% M
Confirms the benefit of JAKi and tocilizumab
Others not so much@RheumNow #ACR23 #ACRBest #abstL03 pic.twitter.com/tRjO31IHiD
— Bella Mehta (@bella_mehta) November 14, 2023